{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-260305","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2023-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.332288+00:00","generated_at":"2026-06-09T16:35:48.904755+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ultragenyx prices $300M public offering of common stock and pre-funded warrants","bullets":["8,333,334 shares at $30.00/share plus 1,666,722 pre-funded warrants at $29.9990 each.","Underwriters exercised option for 1,500,000 additional shares; total net proceeds ~$326.1M.","Offering expected to close October 23, 2023.","J.P. Morgan, Goldman Sachs, BofA Securities, Cowen acted as underwriters."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-260305","json":"https://secwatch.observer/filing/0001193125-23-260305.json","markdown":"https://secwatch.observer/filing/0001193125-23-260305.md","text":"https://secwatch.observer/filing/0001193125-23-260305.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000119312523260305/0001193125-23-260305-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000119312523260305/d524225d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T16:35:48.904755+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c24464822e35d758ba7b0a7bf74302bdbe8a63d","claim":"Ultragenyx Pharmaceutical Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, BofA Securities, Inc., and Cowen and Company, LLC (effective 2023-10-18).","evidence_excerpt":"On October 18, 2023, Ultragenyx Pharmaceutical Inc. (“ Ultragenyx ” or the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, BofA Securities, Inc., and Cowen and Company, LLC (the “ Underwriters ”), providing for the offer and sale in an underwritten public offering (the “ Offering ”) of 8,333,334 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), and in lieu of Common Stock to certain investors, pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase 1,666,722 shares of Common Stock (the “ Warrant Shares ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312523260305/0001193125-23-260305-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, BofA Securities, Inc., and Cowen and Company, LLC"},{"label":"Effective","value":"2023-10-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}